China (Mainland)
Pirfenidone CAS NO.53179-13-8
- Min.Order: 1 Kilogram
- Payment Terms: L/C,T/T,
- Product Details
Keywords
- Pirfenidone
- 53179-13-8
- 5-methyl-1-phenyl-2(1h)-pyridon;
Quick Details
- ProName: Pirfenidone
- CasNo: 53179-13-8
- Molecular Formula: C12H11NO
- Appearance: Off-White Solid
- Application: Pirfenidone has demonstrated activity ...
- DeliveryTime: 12days
- PackAge: in foil bag or customized
- Port: Tianjin xingang
- ProductionCapacity: 10 Metric Ton/Day
- Purity: 99%
- Transportation: by sea or by air
- LimitNum: 1 Kilogram
- Heavy metal: less than 0.4%
- Grade: Industrial Grade
Superiority
Our company is a professional chemical raw materials manufacturer and exporter for many years in chemical market. There are more than 200 excellent staffs and four factories working for us .
Company advantage:
1.Place of Origin in China with Super quality by reasonable price.
2.Fast delivery by safe express way to address specified.
3.Lots of highly qualified engineers and experts to provide technical guideness and support for customers.
4. Sample order are welcome.
5.A variety of payments, such as L/C, TT, , MoneyGram or other payments.
Warm Welcome to contact us to get more products information and details, I will send our product list for your choice.We are Looking forward to our long term cooperation.
Details
| Pirfenidone Chemical Properties |
| mp | 96-97°C |
| storage temp. | Store at RT |
| solubility | DMSO: ≥10 mg/mL, soluble |
| form | solid |
| CAS DataBase Reference | 53179-13-8(CAS DataBase Reference) |
| Clinical application |
1. Idiopathic pulmonary fibrosis degeneration Idiopathic pulmonary fibrosis (IPF) is an unexplained, poor prognosis and high-mortality chronic inflammatory interstitial lung disease. At the same time, PFD is an anti-inflammatory, anti-fibrotic agent which can be used for the treatment of IPF. 2. Liver Fibrosis 3. Renal fibrosis disease 4. Multiple Sclerosis Multiple sclerosis (MS) is a central nervous system-related and the immune-related inflammation and demyelinating diseases. Immune factors relating to it are activation of stellate cells, glial cell, and endothelial cell and the increase of lymphocytes, while PDF have effects of inhibiting the cell activation. 5. Myocardial fibrosis Cardiovascular diseases such as hypertension, cardiomyopathy, and atrial fibrillation can all lead to myocardial fibrosis, thereby resulting in the disease progression or development. Using PDF for treatment of cardiomyopathy caused by Duchenne muscular dystrophy can inhibit myocardial fibrosis, improve the cardiac function. PFD can reduce the incidence of atrial fibrillation and myocardial remodeling through inhibiting fibrosis. 6. Neoplastic diseases: neurofibroma, leiomyoma, and malignant gliomas. 7. Prevention of fibrosis after the organ transplant. 8. Rheumatoid arthritis. |
| Adverse reactions | Common adverse reactions include light sensitivity, fatigue, rash, and nausea; other adverse reactions also include upper gastrointestinal discomfort, bloating, anorexia, diarrhea, and skin itching. |
| Chemical Properties | Off-White Solid |
| Usage | Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver |
| Biological Activity | Antifibrotic agent, effective in models of pulmonary and lung fibrosis. Inhibits collagen production and fibroblast proliferation. Regulates cytokine levels following oral administration in vivo . Potent scavenger of free radicals and inhibitor of lipid peroxidation. |